[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359228-105":59,"doc-detail-359228-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","invariant-natural-killer-t-cells-in-cancer-immunotherapy-lipid-based-modulation-nanotechnology-and-translational-advances","Invariant Natural Killer T Cells in Cancer Immunotherapy - Lipid-Based Modulation, Nanotechnology, and Translational Advances","","Invariant natural killer T (iNKT) cells are a unique lymphocyte subset connecting innate and adaptive immunity by recognizing glycolipid antigens presented via CD1d. After activation with ligands such as α-galactosylceramide (α-GalCer), iNKT cells rapidly release cytokines including IFN-γ and TNF-α, driving dendritic cell, NK cell, and cytotoxic T lymphocyte activation for antitumor effects. Clinical translation is constrained by fast α-GalCer clearance, iNKT anergy after repeated stimulation, and immunosuppressive tumor microenvironment effects. Lipid-engineered nanoparticles improve stability, targeting, and controlled release to sustain Th1-biased activation. In parallel, CAR-engineered iNKT approaches provide antigen-specific targeting while retaining CD1d-restricted immunomodulation, and combination regimens with checkpoint inhibitors, chemotherapy, and cytokine support can counter TME suppression. Remaining barriers include dosing optimization, off-target immune activation control, scalable manufacturing, and long-term safety evaluation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/invariant-natural-killer-t-cells-in-cancer-immunotherapy-lipid-based-modulation-nanotechnology-and-translational-advances/359228/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/invariant-natural-killer-t-cells-in-cancer-immunotherapy-lipid-based-modulation-nanotechnology-and-translational-advances/359228.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do iNKT cells trigger antitumor immunity after activation?","Question",{"text":113,"@type":114},"iNKT cells recognize glycolipid antigens presented by CD1d. After activation with ligands such as α-GalCer, they rapidly secrete cytokines including IFN-γ and TNF-α, which activate dendritic cells, NK cells, and cytotoxic T lymphocytes to promote antitumor responses.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why has clinical translation of iNKT-based immunotherapy been limited?",{"text":118,"@type":114},"Key limitations include rapid clearance of α-GalCer, induction of iNKT cell anergy after repeated stimulation, and suppression caused by the immunosuppressive tumor microenvironment (TME).",{"name":120,"@type":111,"acceptedAnswer":121},"How do lipid-engineered nanoparticles improve iNKT therapeutic performance?",{"text":122,"@type":114},"Lipid-engineered nanoparticle systems improve ligand stability, enhance targeting of antigen-presenting cells, and enable controlled release. These changes help sustain Th1-biased activation and reduce the risk of anergy, while liposomal and polymer-based formulations can increase bioavailability and produce more durable IFN-γ-mediated effects.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359228,1790175800,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nInvariant Natural Killer T Cells in Cancer Immunotherapy: Lipid-Based Modulation, Nanotechnology, and Translational Advances  \nAbdulaziz A. Aloliqi 1, Abdullah M. Alnuqaydan 1, Mohammad Alshebremi 2, Arif Khan 1 and Masood Alam Khan 1, *  \nAcademic Editor: Yutang Wang  \nReceived: 29 January 2026  \nRevised: 28 February 2026  \nAccepted: 8 March 2026  \nPublished: 10 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia; [aaalieky@qu.edu.sa](aaalieky@qu.edu.sa) (A.A.A.); [ami.alnuqaydan@qu.edu.sa](ami.alnuqaydan@qu.edu.sa) (A.M.A.); [4140@qu.edu.sa](4140@qu.edu.sa) (A.K.)  \n2 Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia; [m.alshebremi@qu.edu.sa](m.alshebremi@qu.edu.sa)  \n* Correspondence: [a_khan@qu.edu.sa](a_khan@qu.edu.sa)  \nAbstract  \nInvariant natural killer T (iNKT) cells are a unique lymphocyte subset that bridge innate and adaptive immunity through recognition of glycolipid antigens presented by CD1d. Upon activation by ligands such as α-galactosylceramide (α-GalCer), iNKT cells rapidly secrete cytokines, including IFN-γ and TNF-α, thereby activating dendritic cells, natural killer (NK) cells, and cytotoxic T lymphocytes (CTLs) to promote antitumor immunity. Despite their therapeutic promise, clinical translation has been limited by rapid α-GalCer clearance, induction of iNKT cell anergy following repeated stimulation, and the immunosuppressive tumor microenvironment (TME) . Recent advances in lipid-engineered nanoparticle systems offer solutions to these challenges by improving ligand stability, enhancing antigenpresenting cell targeting, and enabling controlled release that sustains Th1-biased activation while reducing anergy. Liposomal and polymer-based nano-formulations enhance bioavailability and promote more durable IFN-γ-mediated responses. In parallel, chimeric antigen receptor (CAR)-engineered iNKT cells provide antigen-specific tumor targeting while preserving intrinsic CD1d-restricted immunomodulatory functions, demonstrating encouraging safety and efficacy in early-phase studies. Combination strategies further strengthen iNKT-based immunotherapy. Integration with chemotherapy, immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4, and cytokine support enhances effector activation, counteracts TME-induced suppression, and improves therapeutic outcomes. However, challenges remain, including optimization of dosing, control of off-target immune activation, scalable manufacturing, and long-term safety evaluation. Collectively, the convergence of nanotechnology, CAR engineering, and rational combination approaches establishes iNKT cell-based therapy as a promising next-generation immunotherapeutic strategy. Continued refinement of delivery systems, genetic engineering platforms, and translational protocols may enable durable immune reprogramming and improved clinical outcomes in resistant and immunosuppressive cancers.  \nKeywords: cancer immunotherapy; iNKT cells; α-GalCer; nanoparticles; tumor microenvironment  \n1. Introduction  \nCancer remains one of the leading causes of death worldwide, accounting for approximately 9.5 million deaths in 2018, according to the World Health Organization (WHO) [1] . Its high mortality rate is largely attributable to hallmark characteristics such as uncontrolled cellular proliferation, invasive growth, and metastatic dissemination, with metastasis alone responsible for nearly 90% of cancer-related deaths [2] . While localized tumors can often be treated effectively with surgery and radiotherapy, chemotherapy has historically been the cornerstone of treatment for advanced disease. However, its clinical utility","cbCaikHX2ukubBu8","https://ap.wps.com/l/cbCaikHX2ukubBu8","pdf",1896171,22,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"How do iNKT cells trigger antitumor immunity after activation?\",\"answer\":\"iNKT cells recognize glycolipid antigens presented by CD1d. After activation with ligands such as α-GalCer, they rapidly secrete cytokines including IFN-γ and TNF-α, which activate dendritic cells, NK cells, and cytotoxic T lymphocytes to promote antitumor responses.\"},{\"question\":\"Why has clinical translation of iNKT-based immunotherapy been limited?\",\"answer\":\"Key limitations include rapid clearance of α-GalCer, induction of iNKT cell anergy after repeated stimulation, and suppression caused by the immunosuppressive tumor microenvironment (TME).\"},{\"question\":\"How do lipid-engineered nanoparticles improve iNKT therapeutic performance?\",\"answer\":\"Lipid-engineered nanoparticle systems improve ligand stability, enhance targeting of antigen-presenting cells, and enable controlled release. These changes help sustain Th1-biased activation and reduce the risk of anergy, while liposomal and polymer-based formulations can increase bioavailability and produce more durable IFN-γ-mediated effects.\"}]","Invariant Natural Killer T Cells in Cancer Immunotherapy - Lipid-Based Modulation, Nanotechnology, and Translational Advances | PDF",1790136470,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95f4f1ac3ac9a1dfde23a32bed7f1019.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04e2f521ba567454bf5bd0dc697f6227.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13b5b1a67691a9f7f3ce32eaecad40af.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3458c3e83053518ba52675c5564788bb.webp",980,1385]